Open Access

Interference of retroviral envelope with vaccine-induced CD8+ T cell responses is relieved by co-administration of cytokine-encoding vectors

Retrovirology201714:28

DOI: 10.1186/s12977-017-0352-7

Received: 6 March 2017

Accepted: 20 April 2017

Published: 27 April 2017

Abstract

Background

Retroviral envelope (Env) proteins are known to exhibit immunosuppressive properties, which become apparent not only in retroviral infections, but also in gene-based immunizations using retroviral immunogens, where envelope interferes with the induction of CD8+ T cell responses towards another, simultaneously or subsequently delivered, immunogen.

Results

In the Friend retrovirus mouse model, immunization with a plasmid encoding the Friend murine leukemia virus (F-MuLV) Leader-Gag protein resulted in induction of a strong GagL85–93-specific CD8+ T cell response, while the response was completely abrogated by co-immunization with an F-MuLV Env-encoding plasmid. In order to overcome this interference of retroviral envelope, we employed plasmids encoding the cytokines interleukin (IL) 1β, IL2, IL12, IL15, IL21, IL28A or granulocyte–macrophage colony-stimulating factor (GM-CSF) as genetic adjuvants. Co-application of plasmids encoding IL2, IL12, IL21, IL28A and especially GM-CSF rescued the induction of GagL85–93-specific CD8+ T cells in mice vaccinated with FV Leader-Gag and Env. Mice that were immunized with plasmids encoding Leader-Gag and Env and the cytokines IL1β, IL12, IL15, IL28A or GM-CSF, but not Leader-Gag and Env without any cytokine, showed significantly reduced viral loads upon a high-dose Friend virus challenge infection.

Conclusions

Our data demonstrate the potency of cytokine-encoding vectors as adjuvants and immune modulators in composite vaccines for anti-retroviral immunization.

Keywords

Retrovirus Envelope Vaccine Friend virus Friend retrovirus Immunosuppression Adjuvant Immune modulation

Background

The development of an effective anti-retrovirus vaccine has to overcome many challenges, among them the high sequence variability [1], the lack of immune correlates of protection [2, 3], and the immunosuppressive properties of some retroviral proteins. Numerous reports have shown an immunosuppressive effect exerted by retroviral envelope sequences, which is mostly attributed to an immunosuppressive domain located in the transmembrane envelope protein that is highly conserved in exogenous and endogenous retroviral envelope sequences and is an important feature of the ancient retrovirus envelope-derived mammalian syncytin proteins [47]. The immunosuppressive domain has recently been shown to evoke changes in chemokine and cytokine expression patterns, among them an induction of interleukin (IL) 6 and IL10 [8]. While the immunosuppressive effect of envelope in retroviral infection has been reported numerous times, an immunosuppressive effect has rarely been reported in the context of vaccine development. We have demonstrated before that a simultaneous or preceding immunization with an envelope-encoding vector will greatly diminish or even abrogate the CD8+ T cell induction by an otherwise effective vaccine against other immunogens such as another retrovirus-derived protein or the model antigen ovalbumin [9]. Interestingly, we detected envelope-specific IL10-producing CD4+ T cells in the immunized mice which may be involved in the suppression of CD8+ T cell responses towards other immunogens.

The immunosuppressive effect of retroviral envelopes is an important factor to consider in the development of an effective prophylactic vaccine, but it is also likely to affect vaccines used for therapeutic immunization in chronic retrovirus infections, as the immune system is envelope-experienced and furthermore continually exposed to the persistently expressed retroviral envelope protein, and could therefore interfere with therapeutic vaccination efforts. We demonstrated before that the envelope-mediated immune suppression can be circumvented by a sequential immunization where the CD8+ T cell inducing immunogen is applied as a first immunization separate from any envelope component. To generate a more generally applicable solution we now pursued the approach of a co-immunization with cytokine-encoding vectors as genetic adjuvants, aiming to change the cytokine milieu in a way that would favour the induction of CD8+ T cells. We evaluated the cytokines IL1β, IL2, IL12, IL15, IL21, IL28A and granulocyte–macrophage colony stimulating factor (GM-CSF) for their effect on CD8+ T cell induction in a DNA-based immunization, reasoning that these immunostimulatory cytokines might counter-act the envelope-mediated suppression either directly by supplying stimulatory signals for CD8+ T cells or indirectly through their activating effects on antigen-presenting cells.

The experiments presented here were performed in the murine Friend virus (FV) infection model. FV is an immunosuppressive retroviral complex [10] consisting of Friend murine leukemia virus (F-MuLV) and the replication-defective, pathogenic spleen focus forming virus, that causes severe splenomegaly and lethal erythroleukemia in adult mice of susceptible strains, while mice that are genetically resistant to the FV-induced disease develop a persistent infection without overt pathology [11]. Depending on the mouse strain, the FV infection can be a very stringent model for the development of prophylactic vaccines, or for therapeutic interventions such as immunotherapy or therapeutic immunization against an established, chronic infection [1224]. While the FV infection of mice differs in target cell tropism and pathological mechanisms from human retrovirus infections, like the infection with human immunodeficiency virus or human T cell leukemia virus, it is assumed that basic immunological mechanisms that are responsible for the establishment of a chronic infection, and mechanisms required for virus control and clearance, are very similar for these retrovirus infections [25].

We demonstrate here that the co-immunization with F-MuLV envelope-encoding plasmid DNA impairs the induction of Leader-Gag specific CD8+ T cells, and show that co-immunization with plasmids encoding select cytokines relieves this suppression and confers strong protection to highly susceptible mice. To our knowledge, this is the first report showing that envelope-mediated immune suppression can be relieved by co-delivery of cytokines.

Results

Rescue of Env-suppressed GagL85–93-specific CD8+ T cell responses by co-immunization with cytokine-encoding plasmids

We reported before that the co-immunization with Leader-Gag and Env-encoding adenovirus-based vectors leads to an abrogation of the induction of CD8+ T cells specific for the Leader-Gag derived GagL85–93 epitope [9]. To test whether this suppression can be relieved through co-immunization with cytokine-encoding vectors, we used DNA-based immunizations, thereby excluding a possible influence of vector-derived epitopes or vector-specific immune responses, and combined plasmids encoding F-MuLV Leader-Gag and Env with plasmids encoding the murine cytokines IL1β, IL2, IL12, IL15, IL21, IL28A or GM-CSF; all these cytokines have important, direct or indirect, roles in CD8+ T cell priming and survival [2629].

CB6F1 mice were immunized with DNA plasmids encoding Leader-Gag and Env (LG + Env) with and without cytokine-encoding plasmids, or as a control with Leader-Gag-encoding plasmid alone (see Additional file 1: Figure S1 for the vaccination scheme). When the frequency of GagL85–93-specific CD8+ T cells was analysed by MHC I tetramer staining 2 weeks after immunization, we found a strong induction of these cells in most mice immunized with the Leader-Gag-encoding plasmid alone, whereas the response was completely abrogated in mice immunized with the combination of Leader-Gag and Env plasmids (Fig. 1a). While co-immunization with the cytokines IL1β and IL15 resulted mostly in low frequencies of GagL85–93-specific CD8+ T cells which were not significantly different from the LG + Env vaccinated or the unvaccinated control groups, the co-immunization with IL2, IL12, IL21, IL28A and even more so with GM-CSF resulted in significantly improved induction of GagL85–93-specific CD8+ T cell responses. When we analysed the cytokine production of GagL85-93-specific CD8+ T cells, only mice that were immunized with the Leader-Gag plasmid alone had a significantly higher frequency of IFNγ-producing CD8+ T cells compared to unvaccinated mice (Fig. 1b); about half of the mice that were co-immunized with GM-CSF had levels of IFNγ-producing CD8+ T cells comparable to those induced by immunization with Leader-Gag plasmid alone, but responses did not reach statistically significant difference compared to mice immunized with LG + Env.
Fig. 1

Induction of GagL85–93-specific CD8+ T cells by co-immunization with cytokine-encoding plasmids. CB6F1 mice were immunized once with a DNA plasmid encoding Leader-Gag, a mix of plasmids encoding Leader-Gag and Env (LG + Env), or a mix of plasmids encoding Leader-Gag, Env and cytokines as indicated; 25 µg of each plasmid were injected intramuscularly followed by in vivo electroporation. Two weeks after immunization, the frequency of GagL85–93-specific CD8+ T cells in blood cells was analysed by MHC I tetramer staining (a), the production of IFNγ by GagL85–93-specific CD8+ T cells was analysed by intracellular cytokine staining after peptide restimulation (b). Data were acquired in two to four independent experiments with three to four mice per group per experiment. Each dot indicates an individual mouse, the bars indicate the mean values. Data were analysed by Kruskall–Wallis One Way Analysis of Variance on Ranks and Dunn’s multiple comparison procedure, statistically significant differences (P < 0.05) compared to unvaccinated mice are indicated by *, significant differences compared to mice immunized with the combination of Leader-Gag and Env plasmids (LG + Env) are indicated by #

Cytokine-adjuvanted immunization does not interfere with the induction of F-MuLV-binding antibodies

The cytokines were selected for their potential effects on CD8+ T cell induction, but their modulatory effects might well introduce a new bias in the immune response and interfere with antibody induction; therefore, we analysed F-MuLV binding antibody levels after immunization. We found low antibody levels in mice immunized with Leader-Gag plasmid alone or with the combination of Leader-Gag and Env plasmids, and antibody levels of mice that were co-immunized with plasmids encoding IL1β, IL2, IL12, IL15, IL21 or IL28A were not significantly different; interestingly, mice that were co-immunized with GM-CSF had significantly higher binding antibody levels than both unvaccinated mice and mice vaccinated with LG + Env (Fig. 2). These findings demonstrate that the cytokine co-immunization, while rescuing the induction of GagL85–93-specific CD8+ T cells, does not interfere with antibody induction, and can even lead to improved antibody responses.
Fig. 2

Binding antibody responses to plasmid combination vaccines. CB6F1 mice were immunized once with a DNA plasmid encoding Leader-Gag, a mix of plasmids encoding Leader-Gag and Env (LG + Env), or a mix of plasmids encoding Leader-Gag, Env and cytokines as indicated; 25 µg of each plasmid were injected intramuscularly followed by in vivo electroporation. Two weeks after immunization, blood samples were collected and F-MuLV-binding antibodies were analysed. The figure shows absorption values for plasma samples diluted 1:50 in PBS. Data were acquired in two to four independent experiments with three to four mice per group per experiment. Each dot indicates an individual mouse, bars indicate median values. Data were analysed by Kruskall–Wallis One Way Analysis of Variance on Ranks and Dunn’s multiple comparison procedure for statistical significance; statistically significant differences (P < 0.05) compared to unvaccinated mice are indicated by *, significant differences compared to mice immunized with the combination of Leader-Gag and Env plasmids (LG + Env) are indicated by #

Cytokine-adjuvanted immunization induces strong protection from high-dose FV challenge infection

To determine if the rescued induction of GagL85–93-specific CD8+ T cells would result in adequate protection, we performed an FV challenge experiment and infected mice with the high dose of 5000 spleen focus forming units FV 3 weeks after the immunization. To monitor disease development, we palpated the spleens of mice twice a week (Fig. 3a) and found that while mice immunized with Leader-Gag-encoding plasmid alone showed no increase in spleen size over the entire observation period, mice that were immunized with plasmids encoding Leader-Gag and Env had severely enlarged spleens from day 10. Mice that were co-immunized with IL12, IL15, IL28A or GM-CSF on the other hand were able to control disease development and had significantly smaller spleens than unvaccinated mice over the entire observation period.
Fig. 3

Protection from FV challenge infection by co-immunization with cytokine-encoding plasmids. CB6F1 mice were immunized once with a DNA plasmid encoding Leader-Gag, a mix of plasmids encoding Leader-Gag and Env (LG + Env), or a mix of plasmids encoding Leader-Gag, Env and cytokines as indicated; 25 µg of each plasmid were injected intramuscularly followed by in vivo electroporation. Three weeks after immunization, mice were infected with 5000 spleen focus forming units FV. The development of splenomegaly was monitored by palpation of the spleen twice a week (a). Three weeks after FV challenge, mice were sacrificed and spleen weight (b) and viral loads in spleen cells were determined (c). Data were acquired in two to four independent experiments with three to four mice per group per experiment. The bars in (a) indicate the mean values, whiskers indicate the standard error of the means. Each dot (b, c) indicates an individual mouse, bars indicate mean (b) or median (c) values. Data were analysed by Kruskall–Wallis One Way Analysis of Variance on Ranks and Dunn’s multiple comparison procedure, statistically significant differences (P < 0.05) compared to unvaccinated mice are indicated by *, significant differences compared to mice immunized with the combination of Leader-Gag and Env plasmids (LG + Env) are indicated by #

Three weeks after the FV challenge infection, we sacrificed the mice and removed the spleens. At this time point, unvaccinated mice had severely enlarged spleens, while spleens from mice that were immunized with Leader-Gag-encoding plasmid alone showed no increased weight (Fig. 3b). Spleens of about half of the mice that were immunized with Leader-Gag and Env plasmids had a severely increased weight, but mice that were co-immunized with IL1β, IL12, IL15, IL21, IL28A or GM-CSF were able to tightly control splenomegaly, and their spleens were significantly smaller than those of unvaccinated control mice. Similarly, when we analysed the viral load in spleen cells, unvaccinated mice all had very high viral loads, and while some mice immunized with LG + Env had low or even undetectable viral loads, about half of them had very high viral loads comparable with unvaccinated mice, and there was no statistically significant difference between LG + Env immunized and unvaccinated mice. On the other hand, mice that were immunized with Leader-Gag plasmid alone, or mice that were immunized with Leader-Gag and Env in combination with IL1β, IL12, IL15, IL21, IL28A or GM-CSF had significantly reduced viral loads that were below the detection limit in most of the mice (Fig. 3c).

To ascertain that the strong protection observed after co-immunization with cytokine-encoding plasmids was not mediated by direct effects of the cytokines on the FV infection, but in fact attributable to their effects on the FV-specific vaccine-induced immune response, we performed a control experiment and administered only the cytokine-encoding plasmids to CB6F1 mice. We used the cytokines IL1β, IL12, IL15, IL28A and GM-CSF as these cytokines had demonstrated the most profound effects on the viral loads in the co-immunization experiment. Three weeks after cytokine plasmid administration, mice were infected with 5000 spleen focus forming units FV. To monitor disease development, we palpated the spleens of infected mice twice a week, and did not find a significant difference between unvaccinated mice and mice that received the cytokine-encoding vectors (Additional file 2: Figure S2A); similarly, there was no significant difference between the groups in spleen weight (Additional file 2: Figure S2B) or spleen viral loads 3 weeks after FV infection (Additional file 2: Figure S2C). Some of the mice that received the IL12-encoding plasmid exhibited somewhat reduced spleen weight and spleen viral loads, which may indicate a direct or indirect effect of IL12 expression alone on FV infection. On the other hand, application of plasmids encoding IL1β, IL15, IL28A or GM-CSF had no effect on the course of the FV infection.

Our findings demonstrate that cytokine-adjuvanted immunization leads to a rescue of GagL85–93-specific CD8+ T cell responses from envelope-mediated immune suppression and induces strong protection from FV infection.

Discussion

Retroviruses are notorious for their immunosuppressive potential, and while the severe immunodeficiency syndrome associated with progressive HIV infection has to be attributed to the depletion of CD4+ T cells in advanced infection, all retroviruses also exhibit acutely immunosuppressive properties. The immunosuppressive activity is generally assumed to be exerted by a domain in the transmembrane envelope protein which is highly conserved across exogenous and endogenous retroviral envelope sequences [58, 30]. The immunosuppressive properties of retroviral envelope are rarely addressed in immunization studies, and there are only few reports showing a dampening effect of envelope on the immune responses to other immunogens [3134]. We have recently published the observation that immunization with an envelope-encoding adenovirus-based vector leads to a reduction or even abrogation of CD8+ T cell induction to other simultaneously or subsequently delivered immunogens [9]. In contrast to other reports [31], our experiments did not demonstrate a relief of the suppression when the envelope vaccine and the CD8+ T cell inducing vaccine were spatially separated, and while we did not find a significantly changed induction of regulatory CD4+ T cells by envelope-encoding adenovirus in comparison to adenovirus encoding another transgene, we did find production of IL10 by envelope-specific CD4+ T cells, hinting at the establishment of a suppressive cytokine milieu. Because of these changes in the cytokine milieu, we addressed the suppressive effect in the context of DNA immunization and sought to relieve suppression by co-immunization with cytokine-encoding plasmids as genetic adjuvants. For this purpose, we selected the pro-inflammatory cytokines IL1β, IL2, IL12, IL15, IL21, IL28A and GM-CSF, all of which can directly or indirectly influence the induction or maintenance of T cell responses [2629].

We found that IL1β and IL15 had only moderate effects on the induction of GagL85–93-specific CD8+ T cells, whereas IL2, IL12, IL21 and IL28A led to a rescue of GagL85–93-specific CD8+ T cell induction in most of the co-immunized mice; but clearly, GM-CSF had the most profound effect on induction of GagL85–93-specific CD8+ T cell responses in the presence of envelope. GM-CSF has been described before as an adjuvant in DNA- or adenovirus-based immunization against HIV infection or against model antigens [3538], in virus-like particle-based immunization against Hanta virus infection [39], and in experimental cancer immunization in pre-clinical [40] and clinical studies [41, 42]. In all of these studies, GM-CSF was reported to have an enhancing effect on CD8+ T cell responses, which it may exert indirectly by promoting the activation and maturation of dendritic cells [43].

It is assumed that the development of a highly potent anti-retroviral vaccine requires the induction of both cellular and humoral immune responses [4446]; therefore employing a CD8+ T cell promoting cytokine to relieve the envelope-mediated suppression should not interfere with the induction of antibodies and thereby introduce a new bias. Importantly, none of the cytokines tested in our experiments had a diminishing effect on antibody induction, and GM-CSF co-immunization actually resulted in an increase in binding antibody levels, which is well in accordance with the literature that reports a simultaneous promotion of CD8+ T cell and antibody responses by GM-CSF [36]. We showed recently that a rationally designed adenovirus-based vaccine could confer a high level of protection from FV challenge infection similar to the gold standard, attenuated anti-FV vaccine F-MuLV-N, albeit by different mechanisms [9]; indeed the DNA-based, cytokine-adjuvanted vaccine that we present here proves similarly effective, and furthermore might be applicable as a therapeutic vaccine as induction of CD8+ T cell responses does not rely on the vaccinee being envelope naïve.

The envelope-mediated immunosuppression is not only of concern for the development of prophylactic anti-retroviral vaccination strategies, but also for therapeutic vaccine approaches. A chronically infected individual is envelope-experienced and chronically envelope-exposed; furthermore, the chronic phase of FV infection is characterized by an expanded population of regulatory T cells (Treg) [4751] that are creating an immunosuppressed state and interfering with effector functions of CD8+ T cells. Immunotherapeutic interventions targeting regulatory T cells, such as depletion of Treg cells or blocking of inhibitory ligands, have shown effective in reducing viral loads in the chronic FV infection [22, 23]; a combination of a therapeutic immunization using cytokine-adjuvanted DNA vaccines, which circumvents the suppression by envelope, with immunotherapeutic interventions such as Treg depletion and the blockade of inhibitory ligands may result in additive or even synergistic effects on the chronic FV loads and shall be investigated in the future. While IL21 was not the most effective cytokine in the prophylactic immunization, it may be a promising candidate for therapeutic application. IL21 can act on many cellular targets, among them antigen presenting cells such as dendritic cells, but also directly on T cells [52], and it was suggested to be able to substitute for IL2 as a T cell growth factor [53].

Our results show that select cytokines are able to relieve the immunosuppression exerted by retroviral envelope and suggest that cytokine-adjuvanted vaccines may be powerful tools in anti-retroviral vaccine design.

Methods

Cells and cell culture

A murine fibroblast cell line from Mus dunni [54] was maintained in RPMI medium (Invitrogen/Gibco, Karlsruhe, Germany) supplemented with 10% heat-inactivated fetal bovine serum (Invitrogen/Gibco) and 50 µg/ml gentamicin; cells were maintained in a humidified 5% CO2 atmosphere at 37 °C.

Plasmid DNA

The plasmids encoding the F-MuLV proteins Env or Leader-Gag under control of the cytomegalovirus immediate early promoter have been described before [55]. Plasmids encoding the murine cytokines IL2, IL12, IL15, IL21 or GM-CSF are based on the pShuttle-CMV expression plasmid and have been described before [16]. Plasmids encoding murine IL1β or IL28A were constructed by PCR amplification of the coding sequences from cDNA of an influenza-infected mouse lung and subcloning into the pVax plasmid (ThermoFisher Scientific, Darmstadt, Germany). Since mature IL1β does not have a conventional export signal, the leader peptide of the tissue plasminogen activator was added at the N-terminus to allow efficient secretion of the cytokine.

All plasmids were purified by cesium chloride gradient centrifugation and absence of endotoxin contamination was verified by Limulus amebocyte lysate assay (detection limit 0.1 EU/ml; ThermoFisher Scientific, Schwerte, Germany).

Mice

Female CB6F1 hybrid mice (BALB/c x C57BL/6 F1; H-2b/d Fv1b/b Fv2r/s Rfv3r/s) and female BALB/c mice were purchased from Charles River Laboratories (Sulzfeld, Germany). All mice were used when they were between 8 and 9 weeks of age.

Immunization

CB6F1 mice were immunized intramuscularly into the M. gastrocnemius with 25 µg each of the respective plasmids in 30 µl PBS. Immediately following the DNA injection, in vivo electroporation was performed using the BTX AgilePulse system (BTX Molecular Delivery Systems, Holliston, MA) or the Ichor electroporation system (Ichor Medical Systems, San Diego, CA) using electroporation protocols described before [56, 57]. Electroporation with both devices gave similar results.

FV and challenge infection

Uncloned, lactate dehydrogenase-elevating virus (LDV)-free FV stock was obtained from BALB/c mouse spleen cell homogenate (10%, wt/vol) 14 days post infection with a B cell-tropic, polycythemia-inducing FV complex [58]. CB6F1 mice were challenged by the intravenous injection of 5000 spleen focus-forming units.

The development of FV-induced disease was monitored by palpation of the spleens of infected mice twice a week under general anaesthesia, and spleen sizes were rated on a scale ranging from 1 (normal spleen size) to 4 (severe splenomegaly) as described previously [59]. If mice showed overt signs of severe disease before the end of the experiment as rated by pre-determined termination criteria, they were euthanized and excluded from further analysis.

Infectious center assay

Mice were sacrificed 21 days after FV infection by cervical dislocation, the spleens were removed and weighed, and single-cell suspensions were prepared. Serial dilutions of isolated cells were seeded onto M. dunni cells, and cells were incubated under standard tissue culture conditions for 3 days. When cells reached ~100% confluence, they were fixed with ethanol, labelled with F-MuLV Env-specific Mab 720 [60], and then with a horseradish peroxidase-conjugated rabbit anti-mouse Ig antibody (Dako, Hamburg, Germany). The assay was developed using aminoethylcarbazole (Sigma-Aldrich, Deisenhofen, Germany) as substrate to detect foci. Resulting foci were counted, and infectious centers (IC)/108 cells were calculated.

Binding antibody ELISA

For the analysis of F-MuLV-binding antibodies, MaxiSorp ELISA plates (Nunc, Roskilde, Denmark) were coated with whole F-MuLV antigen (5 µg/ml). After coating, plates were blocked with 10% fetal calf serum in PBS, and incubated with plasma dilutions. Binding antibodies were detected using a polyclonal rabbit-anti-mouse HRP-coupled anti-IgG antibody and the substrate tetramethylbenzidine (TMB+; both Dako Deutschland GmbH, Hamburg, Germany); absorption at 450 nm wavelength was analysed after addition of an equal volume of 1 N H2SO4.

Tetramer staining of F-MuLV-specific CD8+ T cells

F-MuLV-specific CD8+ T cells were analysed in peripheral blood 2 weeks after immunization. Erythrocytes were lysed, and cells were stained with PE-coupled MHC I tetramer (containing the H-2Db restricted F-MuLV gag-leader epitope AbuAbuLAbuLTVFL in which cysteine residues of the original amino acid sequence GagL85–93 (CCLCLTVFL) were replaced by amino-butyric acid (Abu) to prevent disulfide bonding [61]; MBL, Woburn, MA), PerCP-anti-CD43, eFluor450-anti-CD8, BV510-anti-CD44 (Becton–Dickinson, Heidelberg, Germany) and Fixable Viability Dye eFluor 780 (eBioscience, Frankfurt, Germany).

Data were acquired on an LSR II flow cytometer (Becton–Dickinson, Mountanview, CA) and analyzed using FlowJo software (Tree Star, Ashton, OR).

Intracellular cytokine staining

For the analysis of effector molecules of GagL85–93-specific CD8+ T cells, cells were stimulated for 6 h in vitro with 1 µg/ml Abu-modified GagL85-93 peptide (AbuAbuLAbuLTVFL; Abu-modified from the original sequence CCLCLTVFL) in the presence of 2 µg/ml brefeldin A. Cells were stained with eFluor450-anti-CD8, PerCP-anti-CD43, BV510-anti-CD44, and FITC-anti-interferon γ (IFNγ; Becton–Dickinson, Heidelberg, Germany).

Data were acquired on an LSR II flow cytometer (Becton–Dickinson, Mountanview, CA) and analysed using FlowJo software (Tree Star, Ashton, OR).

Statistical analyses

Statistical analyses were performed using the software SigmaStat 3.1 (Systat Software GmbH, Erkrath, Germany), testing with Kruskal–Wallis One-Way Analysis of Variance on Ranks and Dunn’s multiple comparison procedure.

Declarations

Authors’ contributions

NB and SW prepared vaccines, NB, DL, SW, MT and WB performed mouse experiments, NB, UD, MT and WB analysed data and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements

NB and DL were supported by the DFG-funded research training group RTG1949/1.

Competing interests

The authors declare that they have no competing interests.

Ethics approval and consent to participate

Mice used in this study were treated in accordance with the guidelines of the University Hospital Essen, Germany, the national law, and the Federation of European Laboratory Animal Science Association. The study was approved by the Northrhine-Westphalia State Office for Nature, Environment and Consumer Protection (LANUV NRW).

Funding

This work was supported by Grants from the Deutsche Forschungsgemeinschaft (TRR60/B4 to WB and UD, BA 4432/1-1 to WB, RTG1949/1 to MT).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Institute for Virology, University Hospital Essen, University Duisburg-Essen
(2)
Department of Molecular and Medical Virology, Institute of Hygiene and Microbiology, Ruhr-University Bochum
(3)
Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg

References

  1. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull. 2001;58:19–42.View ArticlePubMedGoogle Scholar
  2. Heeney JL, Plotkin SA. Immunological correlates of protection from HIV infection and disease. Nat Immunol. 2006;7:1281–4.View ArticlePubMedGoogle Scholar
  3. Pantaleo G, Koup RA. Correlates of immune protection in HIV-1 infection: what we know, what we don’t know, what we should know. Nat Med. 2004;10:806–10.View ArticlePubMedGoogle Scholar
  4. Schlecht-Louf G, Mangeney M, El-Garch H, Lacombe V, Poulet H, Heidmann T. A targeted mutation within the feline leukemia virus (FeLV) envelope protein immunosuppressive domain to improve a canarypox virus-vectored FeLV vaccine. J Virol. 2014;88:992–1001.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Denner J. The transmembrane proteins contribute to immunodeficiencies induced by HIV-1 and other retroviruses. AIDS. 2014;28:1081–90.View ArticlePubMedGoogle Scholar
  6. Mangeney M, Renard M, Schlecht-Louf G, Bouallaga I, Heidmann O, Letzelter C, et al. Placental syncytins: genetic disjunction between the fusogenic and immunosuppressive activity of retroviral envelope proteins. Proc Natl Acad Sci USA. 2007;104:20534–9.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Schlecht-Louf G, Renard M, Mangeney M, Letzelter C, Richaud A, Ducos B, et al. Retroviral infection in vivo requires an immune escape virulence factor encrypted in the envelope protein of oncoretroviruses. Proc Natl Acad Sci USA. 2010;107:3782–7.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Denner J, Eschricht M, Lauck M, Semaan M, Schlaermann P, Ryu H, et al. Modulation of cytokine release and gene expression by the immunosuppressive domain of gp41 of HIV-1. PLoS One. 2012;8:e55199.View ArticleGoogle Scholar
  9. Kaulfuss M, Wensing I, Windmann S, Hrycak CP, Bayer W. Induction of complex immune responses and strong protection against retrovirus challenge by adenovirus-based immunization depends on the order of vaccine delivery. Retrovirology. 2017;14:8.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Friend C. Cell-free transmission in adult Swiss mice of a disease having the character of a leukemia. J Exp Med. 1957;105:307–18.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Hasenkrug KJ, Chesebro B. Immunity to retroviral infection: the Friend virus model. Proc Natl Acad Sci USA. 1997;94:7811–6.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Miyazawa M, Nishio J, Chesebro B. Protection against Friend retrovirus-induced leukemia by recombinant vaccinia viruses expressing the gag gene. J Virol. 1992;66:4497–507.PubMedPubMed CentralGoogle Scholar
  13. Ishihara C, Miyazawa M, Nishio J, Chesebro B. Induction of protective immunity to Friend murine leukemia virus in genetic nonresponders to virus envelope protein. J Immunol. 1991;146:3958–63.PubMedGoogle Scholar
  14. Miyazawa M, Fujisawa R, Ishihara C, Takei YA, Shimizu T, Uenishi H, et al. Immunization with a single T helper cell epitope abrogates Friend virus-induced early erythroid proliferation and prevents late leukemia development. J Immunol. 1995;155:748–58.PubMedGoogle Scholar
  15. Kawabata H, Niwa A, Tsuji-Kawahara S, Uenishi H, Iwanami N, Matsukuma H, et al. Peptide-induced immune protection of CD8+ T cell-deficient mice against Friend retrovirus-induced disease. Int Immunol. 2006;18:183–98.View ArticlePubMedGoogle Scholar
  16. Bayer W, Schimmer S, Hoffmann D, Dittmer U, Wildner O. Evaluation of the Friend virus model for the development of improved adenovirus-vectored anti-retroviral vaccination strategies. Vaccine. 2008;26:716–26.View ArticlePubMedGoogle Scholar
  17. Bayer W, Tenbusch M, Lietz R, Johrden L, Schimmer S, Uberla K, et al. Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection. J Virol. 2010;84:1967–76.View ArticlePubMedGoogle Scholar
  18. Bayer W, Lietz R, Ontikatze T, Johrden L, Tenbusch M, Nabi G, et al. Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes. Retrovirology. 2011;8:75.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Godel P, Windmann S, Dietze KK, Dittmer U, Bayer W. Modification of one epitope-flanking amino acid allows for the induction of friend retrovirus-specific CD8+ T cells by Adenovirus-based immunization. J Virol. 2012;86:12422–5.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Lietz R, Bayer W, Ontikatze T, Johrden L, Tenbusch M, Storcksdieck Genannt BM, et al. Codelivery of the chemokine CCL3 by an adenovirus-based vaccine improves protection from retrovirus infection. J Virol. 2012;86:1706–16.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Akhmetzyanova I, Zelinskyy G, Littwitz-Salomon E, Malyshkina A, Dietze KK, Streeck H, et al. CD137 agonist therapy can reprogram regulatory T cells into cytotoxic CD4+ T cells with antitumor activity. J Immunol. 2016;196:484–92.View ArticlePubMedGoogle Scholar
  22. Dietze KK, Zelinskyy G, Gibbert K, Schimmer S, Francois S, Myers L, et al. Transient depletion of regulatory T cells in transgenic mice reactivates virus-specific CD8+ T cells and reduces chronic retroviral set points. Proc Natl Acad Sci USA. 2011;108:2420–5.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Dietze KK, Zelinskyy G, Liu J, Kretzmer F, Schimmer S, Dittmer U. Combining regulatory T cell depletion and inhibitory receptor blockade improves reactivation of exhausted virus-specific CD8+ T cells and efficiently reduces chronic retroviral loads. PLoS Pathog. 2013;9:e1003798.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Knuschke T, Bayer W, Rotan O, Sokolova V, Wadwa M, Kirschning CJ, et al. Prophylactic and therapeutic vaccination with a nanoparticle-based peptide vaccine induces efficient protective immunity during acute and chronic retroviral infection. Nanomedicine. 2014;10:1787–98.View ArticlePubMedGoogle Scholar
  25. Hasenkrug KJ, Dittmer U. The role of CD4 and CD8 T cells in recovery and protection from retroviral infection: lessons from the Friend virus model. Virology. 2000;272:244–9.View ArticlePubMedGoogle Scholar
  26. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87:2095–147.PubMedGoogle Scholar
  27. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol. 2002;2:251–62.View ArticlePubMedGoogle Scholar
  28. Schluns KS, Lefrancois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol. 2003;3:269–79.View ArticlePubMedGoogle Scholar
  29. Egli A, Santer DM, O’Shea D, Tyrrell DL, Houghton M. The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections. Emerg Microbes Infect. 2014;3:e51.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Bolze PA, Mommert M, Mallet F. Contribution of syncytins and other endogenous retroviral envelopes to human placenta pathologies. Prog Mol Biol Transl Sci. 2017;145:111–62.View ArticlePubMedGoogle Scholar
  31. Bockl K, Wild J, Bredl S, Kindsmuller K, Kostler J, Wagner R. Altering an artificial Gagpolnef polyprotein and mode of ENV co-administration affects the immunogenicity of a clade C HIV DNA vaccine. PLoS One. 2012;7:e34723.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Clutton G, Carpov A, Parks CL, Dean HJ, Montefiori DC, Hanke T. Optimizing parallel induction of HIV type 1-specific antibody and T-cell responses by multicomponent subunit vaccines. AIDS. 2014;28:2495–504.View ArticlePubMedGoogle Scholar
  33. Toapanta FR, Craigo JK, Montelaro RC, Ross TM. Reduction of anti-HIV-1 Gag immune responses during co-immunization: immune interference by the HIV-1 envelope. Curr HIV Res. 2007;5:199–209.View ArticlePubMedGoogle Scholar
  34. Valentin A, Li J, Rosati M, Kulkarni V, Patel V, Jalah R, et al. Dose-dependent inhibition of Gag cellular immunity by Env in SIV/HIV DNA vaccinated macaques. Hum Vaccin Immunother. 2015;11:2005–11.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Ahlers JD, Belyakov IM, Berzofsky JA. Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines. Curr Mol Med. 2003;3:285–301.View ArticlePubMedGoogle Scholar
  36. Ahlers JD, Dunlop N, Alling DW, Nara PL, Berzofsky JA. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. J Immunol. 1997;158:3947–58.PubMedGoogle Scholar
  37. Berzofsky JA, Ahlers JD, Janik J, Morris J, Oh S, Terabe M, et al. Progress on new vaccine strategies against chronic viral infections. J Clin Invest. 2004;114:450–62.View ArticlePubMedPubMed CentralGoogle Scholar
  38. Tenbusch M, Kuate S, Tippler B, Gerlach N, Schimmer S, Dittmer U, et al. Coexpression of GM-CSF and antigen in DNA prime-adenoviral vector boost immunization enhances polyfunctional CD8+ T cell responses, whereas expression of GM-CSF antigen fusion protein induces autoimmunity. BMC Immunol. 2008;9:13.View ArticlePubMedPubMed CentralGoogle Scholar
  39. Cheng LF, Wang F, Zhang L, Yu L, Ye W, Liu ZY, et al. Incorporation of GM-CSF or CD40L enhances the immunogenicity of hantaan virus-like particles. Front Cell Infect Microbiol. 2016;6:185.PubMedPubMed CentralGoogle Scholar
  40. Sakamoto C, Kohara H, Inoue H, Narusawa M, Ogawa Y, Hirose-Yotsuya L, et al. Therapeutic vaccination based on side population cells transduced by the granulocyte-macrophage colony-stimulating factor gene elicits potent antitumor immunity. Cancer Gene Ther. 2017;24(4):165–74.Google Scholar
  41. Duggan MC, Jochems C, Donahue RN, Richards J, Karpa V, Foust E, et al. A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-alpha-2b in patients with CEA-expressing carcinomas. Cancer Immunol Immunother. 2016;65:1353–64.View ArticlePubMedGoogle Scholar
  42. Rini BI, Stenzl A, Zdrojowy R, Kogan M, Shkolnik M, Oudard S, et al. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17:1599–611.View ArticlePubMedGoogle Scholar
  43. Wada H, Noguchi Y, Marino MW, Dunn AR, Old LJ. T cell functions in granulocyte/macrophage colony-stimulating factor deficient mice. Proc Natl Acad Sci USA. 1997;94:12557–61.View ArticlePubMedPubMed CentralGoogle Scholar
  44. Dittmer U, Brooks DM, Hasenkrug KJ. Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection. Nat Med. 1999;5:189–93.View ArticlePubMedGoogle Scholar
  45. Dittmer U, Brooks DM, Hasenkrug KJ. Protection against establishment of retroviral persistence by vaccination with a live attenuated virus. J Virol. 1999;73:3753–7.PubMedPubMed CentralGoogle Scholar
  46. Virgin HW, Walker BD. Immunology and the elusive AIDS vaccine. Nature. 2010;464:224–31.View ArticlePubMedGoogle Scholar
  47. Zelinskyy G, Dietze K, Sparwasser T, Dittmer U. Regulatory T cells suppress antiviral immune responses and increase viral loads during acute infection with a lymphotropic retrovirus. PLoS Pathog. 2009;5:e1000406.View ArticlePubMedPubMed CentralGoogle Scholar
  48. Zelinskyy G, Dietze KK, Husecken YP, Schimmer S, Nair S, Werner T, et al. The regulatory T-cell response during acute retroviral infection is locally defined and controls the magnitude and duration of the virus-specific cytotoxic T-cell response. Blood. 2009;114:3199–207.View ArticlePubMedGoogle Scholar
  49. Zelinskyy G, Kraft AR, Schimmer S, Arndt T, Dittmer U. Kinetics of CD8+ effector T cell responses and induced CD4+ regulatory T cell responses during Friend retrovirus infection. Eur J Immunol. 2006;36:2658–70.View ArticlePubMedGoogle Scholar
  50. Zelinskyy G, Robertson SJ, Schimmer S, Messer RJ, Hasenkrug KJ, Dittmer U. CD8+ T-cell dysfunction due to cytolytic granule deficiency in persistent Friend retrovirus infection. J Virol. 2005;79:10619–26.View ArticlePubMedPubMed CentralGoogle Scholar
  51. Joedicke JJ, Dietze KK, Zelinskyy G, Dittmer U. The phenotype and activation status of regulatory T cells during Friend retrovirus infection. Virol Sin. 2014;29:48–60.View ArticlePubMedGoogle Scholar
  52. Spolski R, Leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol. 2008;26:57–79.View ArticlePubMedGoogle Scholar
  53. Attridge K, Wang CJ, Wardzinski L, Kenefeck R, Chamberlain JL, Manzotti C, et al. IL-21 inhibits T cell IL-2 production and impairs Treg homeostasis. Blood. 2012;119:4656–64.View ArticlePubMedGoogle Scholar
  54. Lander MR, Chattopadhyay SK. A Mus dunni cell line that lacks sequences closely related to endogenous murine leukemia viruses and can be infected by ectropic, amphotropic, xenotropic, and mink cell focus-forming viruses. J Virol. 1984;52:695–8.PubMedPubMed CentralGoogle Scholar
  55. Dittmer U, Werner T, Kraft AR. Co-immunization of mice with a retroviral DNA vaccine and GITRL-encoding plasmid augments vaccine-induced protection against retrovirus infection. Viral Immunol. 2008;21:459–67.View ArticlePubMedGoogle Scholar
  56. Roos AK, Eriksson F, Walters DC, Pisa P, King AD. Optimization of skin electroporation in mice to increase tolerability of DNA vaccine delivery to patients. Mol Ther. 2009;17:1637–42.View ArticlePubMedPubMed CentralGoogle Scholar
  57. Storcksdieck genannt Bonsmann M, Niezold T, Temchura V, Pissani F, Ehrhardt K, Brown EP, et al. Enhancing the quality of antibodies to HIV-1 envelope by GagPol-specific Th cells. J Immunol. 2015;195:4861–72.View ArticlePubMedGoogle Scholar
  58. Chesebro B, Wehrly K, Stimpfling J. Host genetic control of recovery from Friend leukemia virus-induced splenomegaly: mapping of a gene within the major histocompatability complex. J Exp Med. 1974;140:1457–67.View ArticlePubMedPubMed CentralGoogle Scholar
  59. Hasenkrug KJ, Brooks DM, Robertson MN, Srinivas RV, Chesebro B. Immunoprotective determinants in friend murine leukemia virus envelope protein. Virology. 1998;248:66–73.View ArticlePubMedGoogle Scholar
  60. Robertson MN, Miyazawa M, Mori S, Caughey B, Evans LH, Hayes SF, et al. Production of monoclonal antibodies reactive with a denatured form of the Friend murine leukemia virus gp70 envelope protein: use in a focal infectivity assay, immunohistochemical studies, electron microscopy and western blotting. J Virol Methods. 1991;34:255–71.View ArticlePubMedGoogle Scholar
  61. Chen W, Qin H, Chesebro B, Cheever MA. Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J Virol. 1996;70:7773–82.PubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s) 2017

Advertisement